Delivery Order SPE2DR25D3111-SPE2DR26FF3SP
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,933.79 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 40-12.5 mg tablets (30 unit dose packages) with a completion date of November 18, 2025. This competitively awarded, firm fixed price delivery order was issued without set-aside provisions and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,609.92 to AmerisourceBergen Drug Corp for MICARDIS HCT 40-12.5 mg tablets (30-count unit dose packaging), with an ultimate completion date of October 21, 2025. This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order for pharmaceutical supplies supporting federal medical procurement needs. The award was issued to AmerisourceBergen's Corporate Office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,807.12 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 40-12.5 mg tablets (30-count unit dose packaging) with a firm fixed price and completion deadline of December 18, 2025. This non-set-aside competitive award was issued to AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, where the pharmaceutical products will be supplied from. The delivery order represents a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,359.97 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 80-25 mg tablets in unit dose packaging (30 count). This is a firm fixed-price delivery order with an ultimate completion date of September 29, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,524.73 to AmerisourceBergen Drug Corp for Micardis HCT 40-12.5 mg tablets (30-count unit dose packaging), with an ultimate completion date of November 21, 2025. This non-set-aside, competitively awarded contract reflects a firm fixed price delivery order for a brand-name hypertension medication to support federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Micardis HCT 40-12.5 mg tablets (unit dose, 30 count) with a contract value of $3,124.61. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on December 19, 2025, for the supply of Micardis HCT 40-12.5 mg tablets (30-unit dose packages) with a ceiling value of $5,667.72. This is a firm fixed-price delivery order with an ultimate completion date of December 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made through competitive procurement with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $5,163.02 to AmerisourceBergen Drug Corp for the supply of MICARDIS HCT 40-12.5 mg tablets in unit dose packaging (30 count) on September 2, 2025, with completion expected by September 3, 2025. This contract was awarded on a non-competitive, firm fixed-price basis and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at approximately $1 billion through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,093.19 to supply Micardis HCT 80-25 mg tablets (undivided 30 count) with a firm fixed price structure. The order was competitively awarded with no set-aside designation and carries an ultimate completion date of December 5, 2025. AmerisourceBergen will fulfill this requirement from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order valued at $2,659.44 to AmerisourceBergen Drug Corp on December 15, 2025, for the supply of Micardis HCT 80-25 mg tablets in unit dose packaging (30-count). This firm fixed-price contract, which is not set-aside designated, calls for delivery by December 16, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child order under the company's larger Indefinite Delivery...
- SPE2DR25D3111Indefinite Delivery Contract
- SPE2DR25D3111-SPE2DR26FF3SPDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,552.43 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 40-12.5 mg tablets in unit dose packaging (30-count) on December 22, 2025, with completion expected by December 23, 2025. This competitively awarded, firm fixed-price delivery order was placed against AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), a $999.999 billion prime vendor agreement extending through December 2026 that serves as the primary vehicle for pharmaceutical and medical supply distribution to support military healthcare systems globally. The delivery will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp has established itself as a key supplier to the Defense Health Agency and other government healthcare systems through its extensive IDC portfolio. The company's federal contract awards demonstrate consistent capability in delivering a comprehensive range of pharmaceutical products—including brand-name and generic medications, specialty treatments, vaccines, and medical supplies—across multiple therapeutic domains to support military readiness and veteran healthcare requirements. This particular delivery order represents a routine execution of the larger prime vendor contract designed to ensure continuous pharmaceutical supply chain support to the Department of Defense medical infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 12/21/25 |